News & events

Events

Upcoming and recent investor, scientific and corporate events.

See where Curasight is presenting, participating in conferences or hosting investor and scientific events.

Nov

2026

Conference

Jefferies Global Healthcare Conference in London

16–19 November 2026

Curasight’s management team has been invited to attend and host meetings at the Jefferies Global Healthcare Conference in London on November 16 – 19, 2026.

The conference is a unique opportunity to showcase our advancements and engage directly with key industry leaders and investors.

Please reach out at info@curasight.com to arrange a meeting.

Jan

2027

Conference

The 45th Annual J.P. Morgan Healthcare Conference in San Francisco

11–14 January 2027

Curasight’s management team has been invited to attend the 45th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11–14, 2027.

Curasight looks forward to engaging with investors and industry leaders and share an update on the company’s ongoing progress and future development plans for its uPAR-targeted theranostic platform.

Please reach out at info@curasight.com to arrange a meeting.

2026

Annual general meeting 2026

2025

Extraordinary general meeting

29 December 2025

Follow Curasight’s progress

News & events

Investor and scientific presentation materials.

Investors

Financial Calendar

Key reporting dates and investor events.

News & events

Receive Curasight news and market announcements.

Curasight A/S is a clinical-stage radiopharmaceutical company developing products targeting uPAR, a target associated with aggressive cancer biology and a cancer target expressed across solid tumor types. The portfolio is organized through uTRACE®, the imaging and diagnostic platform, and uTREAT®, the therapeutic development platform comprising clinical stage glioblastoma programs and a next-generation uPAR-targeting ligand designed for modular alpha and beta payloads for additional solid tumor types.

Investigational product statementTherapeutic product candidates within the uTRACE® and uTREAT® platform are investigational and they have currently not been approved for commercial use by any regulatory authority.

Forward-looking informationCertain information on this website may contain forward-looking statements regarding development plans, clinical milestones, regulatory activities, partnerships and other future events. Such statements involve risks and uncertainties, and actual outcomes may differ materially. Users should refer to Curasight’s latest market announcements and financial reports for current information.

Medical information statementInformation on this website is provided for general corporate and scientific information only and is not intended as medical advice. Patients should consult qualified healthcare professionals regarding diagnosis and treatment decisions.

+45 22 83 01 60 · info@curasight.com

Copyright 2026 © Curasight